Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (Nasdaq: TNGX) is a clinical-stage biopharmaceutical company focused on precision oncology, developing cancer therapies built on the principle of synthetic lethality. The company entered public markets in 2021 through its merger with BCTG Acquisition Corp., a blank-check vehicle that completed its IPO in 2020 under the sponsorship of BCTG Sponsor LLC, an affiliate of healthcare investor BVF Partners L.P. Tango submitted a Form 8-K to the Securities and Exchange Commission on May 13, 2026, flagging a material corporate development. Investors and analysts tracking SPAC-origin biotech names can sign up at SpacDesk for full filing histories, deal analytics, and real-time alerts on TNGX and the broader post-merger universe.